Gilead Sciences Inc
GILD:NASDAQ
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 55.18 | -1.18 -2.09% | 0.00% | 3,341,407 | 14.2M |
Market data is delayed by at least 20 minutes.
Latest News Headlines for Gilead Sciences Inc
Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
-- Regimen Achieves 97 Percent Overall Response Rate with Estimated Progression-Free Survival at 24 Months of 93 Percent --
-- Results from Study 101-08 and Other Idelalisib Clinical Studies to Be Presented at American Society of Clinical Oncology Annual Meeting --
Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15
View more recent headlines
Webcast Available Through Gilead Corporate Website
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 14, 2013--
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.
Company Background
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 56.60 | Previous Close 56.36 |
Day High 56.64 | Day Low 54.90 |
52wk High/Date 57.10 / 5/15/2013 | 52wk Low/Date 24.12 / 6/5/2012 |
% off 52wk High -3.36% | % off 52wk Low 128.77% |
Beta (5 Yr) 0.5 | Market Capitalization 84.2B |
Shares Outstanding 1.5B | Volatility Avg 29.31 |
EPS(TTM) 1.51 | P/E Ratio 36.6x |
Dividend Announcement -- | Dividend Yield 0.00% |
Ex-Date -- | Date of Record -- |
Payable 0.00 - -- | Payable Date -- |
Last Trade as of 5/16/2013 10:41 AM ET | |
GILD Gilead Sciences Inc vs. Peers
| Peers | |
|---|---|
GILD Gilead Sciences Inc | 53.46% |
Abbott Laboratories | 20.17% |
Merck & Co., Inc. | 14.14% |
Pfizer Inc. | 17.87% |
GILD Gilead Sciences Inc | 0.00% |
Abbott Laboratories | 1.49% |
Merck & Co., Inc. | 3.68% |
Pfizer Inc. | 3.25% |
GILD Gilead Sciences Inc | -2.09% |
Abbott Laboratories | -1.51% |
Merck & Co., Inc. | -0.94% |
Pfizer Inc. | -0.57% |